Opus Genetics, Inc.

IRD

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Perceptive Advisors

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Perceptive AdvisorsNEWFeb 17, 2026

Shares: 4,325,000Value: $8.7M

# Signal Note: Perceptive Advisors Initiates 4.3M Share Position in Opus Genetics Perceptive's $8.7M entry into Opus signals conviction in the biotech's inherited retinal disease (IRD) pipeline, likely driven by upcoming clinical data or regulatory milestones. Edelman's fund has demonstrated strong selectivity in clinical-stage bets, suggesting meaningful near-term catalysts justify the ~4% stake entry point.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

IVVD1 fund KRYS1 fund BLLN1 fund DXCM1 fund ENSCW1 fund GRAL1 fund IKT1 fund AMLX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: